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The interaction of leech-derived tryptase inhibitor
(LDTI) with bovine liver capsule tryptase (BLCT) and
bovine trypsin has been studied using both thermo-
dynamic and kinetic approaches. Several differences
were detected: (i) the equilibrium affinity of LDTI for
BLCT (Ka = 8.9  105 M–1) is about 600-fold lower than
that for bovine trypsin (Ka = 5.1  108 M–1); (ii) LDTI be-
haves as a purely non-competitive inhibitor of BLCT,
while it is a purely competitive inhibitor of bovine tryp-
sin. These functional data are compared with those
previously reported for the LDTI binding to human
tryptase, where tight inhibition occurs at two of the
four active sites of the tetramer (Ka = 7.1  108 M–1).
Amino acid sequence alignment of BLCT, human II-
tryptase and bovine trypsin allows us to infer some
possible structural basis for the observed functional
differences. 
Key words: LDTI / Mast cell tryptase / Protease inhibitor /
Trypsin.
Introduction
Tryptases are the major trypsin-like proteases of mast cell
secretory granules (Schwartz, 1990). They have been iso-
lated from a variety of organisms, such as man (Smith et
al., 1984; Cromlish et al., 1987; Harvima et al., 1988), rat
(Kido et al., 1985; Braganza and Simmons, 1991), dog
(Schechter et al., 1988), and cow (Fiorucci et al., 1992).
Bovine liver capsule tryptase (BLCT) is an oligomer with an
apparent Mr of 360 000, composed of 35–38 kDa sub-
units (Erba et al., 1998), displaying about 75% identity in
amino acid sequence with tryptases from other species
(Pallaoro et al., 1996). Stability and enzymatic activity of
BLCT, as well as of human tryptase, is affected by several
factors including time, presence of glycerol, ionic strength
and glycosaminoglycan interaction (Schechter et al.,
1993, 1995; Addington and Johnson, 1996; Erba et al.,
1998).
Binding studies have shown that the Kunitz-type bovine
pancreatic trypsin inhibitor (BPTI) is able to inhibit BLCT in
vitro (Fiorucci et al., 1995a); co-localization of the inhibitor
and the protease in the same compartment of bovine mast
cells (Fiorucci et al., 1995b) has suggested a physiological
significance for this interaction. Interestingly, endogenous
inhibitors, able to modulate human tryptase activity, have
not been found yet. So far the only natural inhibitor known
for human tryptase is a small 46 amino acid protein, which
has been isolated from the leech Hirudo medicinalis and
named LDTI (leech-derived tryptase inhibitor; Sommer-
hoff et al., 1994). LDTI inhibits trypsin and chymotrypsin
activity with a Ki of 0.9 nM and 20 nM, respectively, while
inhibition of human tryptase occurs with a Ki of 1.4 nM
(Sommerhoff et al., 1994; Stubbs et al., 1997).
Here we report an investigation on the LDTI binding to
both BLCT and bovine trypsin, using a steady-state kinet-
ic approach to measure the equilibrium and kinetic prop-
erties of the interaction. The results obtained are com-
pared with those reported previously for the inhibition of
human tryptase by LDTI (Sommerhoff et al., 1994; Stubbs
et al., 1997). On the basis of the amino acid homology, a
possible structural basis is suggested to explain the func-
tional differences between bovine and human tryptases.
Results
Binding experiments of LDTI to bovine trypsin (Figure 1A)
yielded a value of Ka = 5.069 (±0.3) 10
8 M–1, in good
agreement with the already reported values of Ki = 0.9–
1.8 nM (Sommerhoff et al., 1994). Data points were fitted
according to a linkage scheme (Wyman, 1964) and the fol-
lowing general equation was employed for the analysis of
the trypsin-LDTI interaction:
y = 1– (Kax / (1+ Kax)) Equation 1
where y is the fraction of residual activity, x is the concen-
tration of free inhibitor and Ka is the equilibrium associa-
tion constant. The calculated curve is compatible with a
simple competitive mechanism for trypsin inhibition by
LDTI. This finding is in line with the crystal structure of the
complex between LDTI and porcine trypsin (Di Marco and
Priestle, 1997; Stubbs et al., 1997), which shows that the
inhibitor binds to the active site of trypsin in a substrate-
like manner with residue P1 (Lys8) interacting with residue
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Asp 189 in the primary specificity pocket of the enzyme.
On the other hand, LDTI binding to BLCT (Figure 1B)
displays markedly different features, suggesting a differ-
ent interaction mechanism, which was analyzed with a
modified formula, namely
y = 1– (Kax / (1+ Kax))Q Equation 2
where all parameters have the same meaning as in Eq. 1,
and Q represents the maximum inhibition obtained. The
best fits were calculated with a non-linear regression
analysis using a Marquardt algorithm.
The binding constant Ka = 8.9 (±3.2)10
5 M–1 is about
three orders of magnitude lower than that found for
trypsin, indicating a low stability of the BLCT-LDTI com-
plex. The most striking difference compared to the
trypsin-LDTI interaction is given by the finding that, even
at high inhibitor concentration, the BLCT-LDTI binding
curve displays an asymptotic residual activity, amounting
to about 13% (corresponding to Q = 0.87 in Eq. 2), as if a
certain percentage of the enzyme is never inhibited by
LDTI. The presence of other contaminating serine pro-
teases can be ruled out, since only two [3H]-DFP labeled
bands corresponding to tryptase were detected on SDS
gels. Thus, the behavior shown in Figure1B can be ac-
counted for by the interaction of LDTI at a binding site dif-
ferent from the primary specificity pocket, decreasing the
catalytic rate constant kcat according to a non-competitive
inhibitory mechanism.
In order to test this possibility, we carried out a steady-
state kinetic investigation at different substrate and in-
hibitor concentrations (Figure 2). The results obtained
indeed suggest a simple non-competitive inhibitory
mechanism because the data can be described by an in-
hibitor-independent Km of 4.310
–5 M–1 and an inhibitor-
dependent kcat according to the formula
obskcat = 
0kcat (1 – (Ka[I] / (1 + Ka[I]))Q) Equation 3
where obskcat is the observed catalytic rate constant, 
0kcat
(= 7.0 s–1, see Table 1) is the catalytic rate constant in the
absence of LDTI, Ka (8.910
5 M–1) and Q (0.87) have the
same meaning as in Eq. 2. 
The different interaction mechanism of LDTI with
bovine trypsin and BLCT was further investigated by
studying the kinetic aspects of the interaction of LDTI with
the two enzymes. Figure 3A shows the progress curves
obtained for bovine trypsin, applying Scheme 1 for a pure-
ly competitive inhibition, to fit the kinetic parameters:






where Km is the Michaelis-Menten constant, Ka is the in-
hibitor association binding constant to the free enzyme
and kcat is the catalytic rate constant. The continuous lines
of Figure 3A were obtained with the same set of kinetic rate
constants, the various curves referring to different LDTI
Fig.1 Binding of LDTI to Bovine Trypsin (A) and Bovine Tryptase
(B). 
Bovine trypsin (0.5 nM active sites), or BLCT (2.5 nM active sites)
were incubated in 0.1 M Tris-HCl pH 8.0, at 30°C for 30 min with
increasing amounts of LDTI. Residual enzymatic activity was
assayed using Boc-Phe-Ser-Arg-MCA as a substrate. The con-
tinuous lines in panels (A) and (B) represent the best fit of data
using Eq. 1 and Eq. 2, respectively.
Fig. 2 Lineweaver-Burk Plots of Bovine Tryptase (5 nM Active
Sites) in the Absence () and in the Presence of 4.2 M () and 
8.4 M LDTI (). 
The mixtures were incubated for 30 min at 30°C in 0.1 M Tris-HCl
pH 8.0. The residual proteolytic activity of each incubation mix-
ture was then measured in the presence of different concentra-
tions of Boc-Phe-Ser-Arg-MCA as a substrate. 
Table 1 Catalytic and LDTI Binding Parameters of Bovine




–1) 14.7 ± 1.2 7.0 ± 0.9 
Km (M) 3.05 (± 0.4) 10
–5 4.0 (±1.0) 10–5
LDTI binding parameters
Ka (M
–1) 5.08 (± 0.24) 108 8.9 (± 3.2) 105
kon (M
–1 s–1) 3.3 (± 0.4) 105 4.2 (±1.3) 103
koff (s
–1) 6.6 (±1.9) 10–4 4.7 (±1.5) 10–3
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concentrations; the only constraint imposed on the values
of rate constants was that kon/koff = Ka. It is evident that
Scheme 1 is appropriate for describing the kinetics of LDTI
binding to trypsin, confirming that the interaction follows a
simple competitive mechanism.
Figure 3B displays the progress curves obtained with
BLCT at different concentrations of LDTI. The dashed line
represents the best fit according to Scheme 1 obtained 
at the highest inhibitor concentration used (16 M); it is
obvious that a simple competitive mechanism does not
properly describe the dynamic behavior of LDTI binding 
to BLCT. We have then attempted a description of the
system according to Scheme 2:




Ka   Scheme 2↓ ↓
EI + S ←→ ESI ←→ EI + P
Km kcat
considering a purely noncompetitive mechanism, where
Ka, Km and kcat have the same meaning as in Scheme 1. 
is the interaction factor between the binding of inhibitor (or
substrate) to the free enzyme and that to the substrate-
bound (or inhibitor-bound) enzyme, with  > 1 for a posi-
tive interaction,  < 1 for a negative interaction and  = 1 for
a purely noncompetitive mechanism.  is the interaction
factor for the rate of substrate catalysis between the ES
complex and the ESI complex, with  > 1 if the ESI form is
catalyzed more quickly than ES, and  < 1 if the opposite
is observed. Data points were analyzed setting  = 1 (i. e.,
the inhibitor does not affect the intrinsic affinity of sub-
strate for the enzyme and vice versa) and  = 0.13 (corre-
sponding to the ratio of kcat for ESI and ES species, see
Scheme 2). The continuous lines in Figure 3B correspond
to such a mechanism. The various curves employ the
same set of rate constants and refer to different LDTI con-
centrations, with the same constraint imposed for LDTI
binding to trypsin (i. e. kon/koff = Ka). Scheme 2 indeed ap-
pears considerably more appropriate for a quantitative
description of the BLCT-LDTI binding.
An important aspect of the applicability of the scheme
concerns the reliability of kinetic parameters reported in
Table 1. Thus, a too slow dissociation rate constant for the
BLCT-LDTI complex (i. e. <10–5 s–1) might impair the valid-
ity of data reported in Figure 2, since in such a case reequi-
libration after incubation would be too slow to be com-
plete during the steady-state observations. Therefore, we
carried out a direct measurement of the complex dissoci-
ation process, incubating the enzyme and the inhibitor
under conditions in which about 70% enzyme inhibition
occurs. 10-fold dilution of this incubation mixture into the
assay buffer containing the substrate induces a shift to-
ward a new equilibrium by dissociation of the inhibitor
from the enzyme. The substrate cleavage, monitored as a
function of time, corresponds to the progressive dissocia-
tion of the inhibitor/enzyme complex. Figure 3C shows
data obtained from this experimental approach and the
continuous line is the expected behavior of the system ac-
cording to the parameters reported in Table 1. It is immedi-
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Fig. 3 Kinetics of the Interaction of LDTI with Bovine Trypsin and
BLCT. 
(A) Bovine trypsin-LDTI association. Enzymatic activity of bovine
trypsin (0.5 nM active sites) toward Boc-Phe-Ser-Arg-MCA in 
0.1 M Tris-HCl pH 8.0, at 30°C, was recorded for 40 min in the ab-
sence () or in the presence of 1.65 nM () and 4.26 nM () LDTI.
Continuous lines represent the best fit of data using an equation
based on a competitive mechanism of inhibition (see Scheme 1).
(B) BLCT-LDTI association. Enzymatic activity of BLCT (2.5 nM
active sites) was recorded under the same conditions, either in
the absence () or in the presence of 2 M () and 16 M () LDTI.
Continuous lines represent the best fit of data using an equation
based on a noncompetitive mechanism of inhibition (see Scheme
2). The dashed line represents the fitting of the progress curve ob-
tained at the highest LDTI concentration, according to Scheme 1
(competitive inhibition mechanism). (C) BLCT-LDTI complex dis-
sociation. BLCT (50 nM active sites) was incubated with 2 M LDTI
in 200 l of 0.1 M Tris-HCl, pH 8.0, for 30 min at 30°C. BLCT-LDTI
complex dissociation was then measured by monitoring enzy-
matic activity for 30 min after 10-fold dilution with the same buffer
(). The continuous line represents the theoretical progress curve
of the equilibrium relaxation calculated with the rate constants
deriving from the fitting of the BLCT-LDTI association curve. The
onset of the theoretical progress curve is shown in the inset.
Ka
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ately evident that the rate constants are appropriate for a
quantitative description of the inhibitor association and
dissociation processes, further reinforcing the interpreta-
tion according to Scheme 2. It must be noted that the
shape of the progress curve reported in Figure 3C does not
show the expected upward curvature corresponding to
the increase of enzyme activity following inhibitor disso-
ciation. The inconsistency is only apparent since such an
increase occurs in the very early stages of the process
(within the first 20 s), confirming the relatively fast disso-
ciation constant (see Figure 3C inset). The upward curva-
ture occurs at a time interval much shorter than the actual
half-time of the inhibitor dissociation process (about 2 min
according to the koff value reported in Table 1), simply be-
cause the difference in the rate for substrate catalysis,
before and after the inhibitor dissociation, is such that the
inhibitor-free species dominates the apparent rate of sub-
strate catalysis. Thus the shift in equilibrium occurs in a
relatively short time ensuring that the observation time of
the steady-state measurements is sufficient to guarantee
the establishment of the equilibrium.
Discussion
A comparison between the kinetic and thermodynamic
parameters obtained for bovine trypsin and BLCT (Table 1)
indicates that the ~ 600-fold different affinity of LDTI for 
the two enzymes is mostly due to the kinetic association
process (kon values differ ≈ 80-fold) suggesting the pres-
ence of an energetic barrier (amounting to G≠~11 kJ/
mol) hindering the formation of the enzyme-inhibitor com-
plex. A much smaller difference is observed for the com-
plex dissociation, which is only 7-fold faster in BLCT than
in trypsin, indicating that once the EI complex is formed its
stability is not drastically different between the two en-
zymes. A structural interpretation of this difference is not
straightforward, also in view of the fact that the different
inhibition mechanism for the two enzymes may imply a
somewhat different enzyme-inhibitor interaction site.
However, independently of this uncertainty, the decreased
association rate and the faster dissociation rate constant
of LDTI observed in BLCT with respect to bovine trypsin
(see Table 1) suggests a weaker interaction of the LDTI P1
residue with the primary specificity pocket in bovine
tryptase (Erba et al., 1998). Such a feature reflects the
Asp189 replacement by Asn189 in BLCT (Figure 4), which
results in a decreased negative charge at the bottom of the
pocket with respect to that of bovine trypsin and human
II-tryptase. This difference might account for the much
higher affinity of LDTI for human II-tryptase with respect
to BLCT. However, at nanomolar concentrations LDTI in-
duces only 50% inhibition of the human tryptase tetramer
(Sommerhoff et al., 1994). Other structural differences be-
tween bovine and human II-tryptase may be considered.
Thus, modeling of the LDTI-human tryptase complex, as
well as inhibition experiments of human II-tryptase with
recombinant LDTI variants (Stubbs et al., 1997), indicate
that the complex formation is favored by the juxtaposition
of Lys1-Lys2 at the N-terminus of LDTI with residues
Asp143 and Asp147 of the 147 loop of the tryptase
monomer where LDTI is bound (Pereira et al., 1998;
Sommerhoff et al., 1999). This interaction is impaired in
BLCT, since the 147 loop lacks Asp143 and Asp147,
which are substituted by Asn and Gly, respectively (Fig-
ure 4). Another relevant structural difference between
human and bovine tryptase is the substitution of Arg173
with a Pro residue in bovine tryptase (Figure 4). This
residue, located at the end of the 173 flap, may force this
structure to assume a conformation resulting in an active
site more accessible to macromolecular inhibitors such as
LDTI or BPTI (Fiorucci et al., 1995a). It is noteworthy that
rat tryptase shows a Pro residue in the same position and
is inhibited by macromolecular inhibitors (Braganza and
Fig. 4 Amino Acid Sequence Alignment of BLCT, Human II-Tryptase and Bovine Trypsin. 
Multiple sequence alignment was performed using the ClustalW program. Identical amino acids are shaded. The six surface loops
involved in the contacts between monomers in human II-tryptase (Pereira et al., 1998) are underlined. Numbering refers to the
chymotrypsinogen sequence.
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Simmons, 1991), similarly to BLCT. Moreover, many se-
quence changes occur at the six surface loops (Figure 4),
which, in the human II-tryptase tetramer, are involved in
the two different kinds of contacts between subunits
(Pereira et al., 1998). Changes in the loop sequence and
length were pointed out recently for human and mouse
TMT (transmembrane tryptases) with respect to human
II-tryptase, and it was suggested that it is unlikely that
these new members of the tryptase family form a similar
tetrameric structure as in human II-tryptase (Wong et al.,
1999). Likewise, a different pattern of interaction among
monomers could occur in BLCT, with a possible change in
the central oval pore geometry, which could become more
accessible to macromolecular inhibitors.
Finally, is worth remembering that the endogenous
tryptase inhibitor (BPTI) is contained in bovine mast cells
(Fiorucci et al., 1995b), and this may have some peculiar
influence on the role and on the functional properties of
bovine tryptase. Therefore, it appears likely that tryptases
from different species differ more than expected in respect
to activity, regulation, and inhibition, and that this may be
related to different metabolic aspects in the various
species.
Materials and Methods
BLCT was isolated and purified as previously described (Fiorucci
et al., 1992). The fresh stock solution (2–4 M active sites in 10 mM
MES, 2 M NaCl, pH 6.1) was titrated and used directly for the inhi-
bition experiments. The enzyme preparation was labeled with
[3H]-diisopropyl fluoro-phosphate and subjected to SDS-PAGE.
Autoradiography of the gel showed only the doublet band corre-
sponding to tryptase. rLDTI was obtained and purified as previ-
ously reported (Auerswald et al., 1994; Pohlig et al., 1996). Bovine
trypsin (type XIII) and the fluorogenic substrate Boc-Phe-Ser-Arg-
MCA were purchased from Sigma-Aldrich. All other chemical
products were of analytical grade.
Equilibrium Binding Experiments
Steady-state experiments were performed in 0.1 M Tris-HCl, pH
8.0 (assay buffer) at 30°C. BLCT (2.5 nM active sites) or bovine
trypsin (0.5 nM active sites) were incubated for 30 min with differ-
ent amounts of LDTI and then assayed for proteolytic activity us-
ing Boc-Phe-Ser-Arg-MCA as a substrate (14 M). The fluores-
cence of 7-amino-4-methyl-coumarin (MCA) released from the
substrate was monitored in a thermostated spectrofluorimeter
Kontron SFM25 (excitation at 370 nm, emission at 460 nm; Pal-
laoro et al., 1996). The signal was recorded for at least five min-
utes. A plot of residual activity versus free inhibitor concentration
was generated. 
For the determination of the inhibition mechanism, Km and Vmax
values for the hydrolysis of Boc-Phe-Ser-Arg-MCA were ob-
tained by measuring tryptase activity in the assay buffer at 30°C
at different substrate concentrations (i. e., 1 –70 M), in the pres-
ence of two concentrations of LDTI (i. e. 4.2 and 8 M), following
30 min pre-incubations. Data were processed into Lineweaver-
Burk plots.
Kinetic Experiments
Kinetic measurements were performed in the assay buffer at
30°C, by rapidly mixing the enzyme (5.0 nM BLCT or 0.5 nM
trypsin), Boc-Phe-Ser-Arg-MCA (14 M) and LDTI at different
concentrations. Proteolytic activity was assayed as described
above in the spectrofluorimeter. The progress curves were
recorded for at least 30 min. Data points were plotted in terms of
product release as a function of time, and analyzed according to
Scheme 1 (for a purely competitive inhibition) and Scheme 2 (for a
noncompetitive inhibition) as described in the Results section. Ki-
netic parameters were obtained by an iterative least-squares fit-
ting procedure employing our own program running under the
MATLAB environment (The Student Edition of MATLAB, 1992). A
set of differential equations was used for each species represent-
ed in the proposed scheme(s) according to the Runge-Kutta
method (Smith, 1978). At each step the concentrations of all mol-
ecular species, including free substrate, free enzyme and free in-
hibitor were recalculated and updated. For fast equilibria, such as
the process concerning Km, we considered the ratio [ES]/[E] [S]
constant over the time range of the phenomena observed, there-
fore no specific experimental conditions are required to describe
the kinetic progress curves and to determine kinetic parameters. 
The kinetic dissociation constant for the BLCT-LDTI complex
was evaluated by incubating BLCT (50 nM active sites) and LDTI
(2 M) in 200 l of the assay buffer for 30 min at 30°C, a condition
that ensures a 70% enzyme inhibition (see Figure 1B). 1.8 ml of the
same buffer containing 14 M Boc-Phe-Ser-Arg-MCA were then
added. The new concentration condition induces a shift toward a
new equilibrium in which no more than 20% enzyme inhibition
occurs. The fluorescence signal recorded for 30 min after mixing
corresponds to the enzyme activity, which increases following
LDTI dissociation and can be simulated employing the same
Runge-Kutta program utilized for the association kinetic con-
stants (see above).
Standard deviations were derived from several experiments 
(at least three for each experimental condition).
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